CNBC TV

AstraZeneca shares dropped on Monday after reports that the company had discussed a potential mega-merger with Bristol Myers Squibb, a deal that analysts said would be a surprising strategic move for one of the pharmaceutical industry's strongest growth stories.

CNBC's Annika Kim Constantino explains.

Read more at the link in bio.